Summary tables comparing neoplastic disorders: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
|colspan="1" style = "width: 20%; background:#006699;color:white;font-size:80%"|40:80 | |colspan="1" style = "width: 20%; background:#006699;color:white;font-size:80%"|40:80 | ||
|colspan="1" style = "width: 20%; background:#004466;color:white;font-size:80%"|>80 | |colspan="1" style = "width: 20%; background:#004466;color:white;font-size:80%"|>80 | ||
|} | |} | ||
</div> | </div> | ||
Revision as of 15:15, 7 July 2023
| KEY | <5% | 5-20 | 20:40 | 40:80 | >80 |
| Immunophenotype LPD | ||||||
|---|---|---|---|---|---|---|
| Marker | CLL | MCL | FL | MZL | HCL | DLBCL |
| κ/λ | 40:80 wk | >80 | 40:80 var | >80 | >80 stg | 40:80 var |
| FMC7 | 20:40 wk | 40:80 | 20:40 wk | 40:80 | >80 Stg | 20:40 var |
| CD5 | >80 | >80 stg | <5% | 5-20 | 5-20 | 5-20 |
| CD10 | 5-20 | 5-20 | >80 Stg | 5-20 | 5-20 | 40:80 |
| CD11C | 20:40 wk | 20:40 wk | <5% | 40:80 | >80 Stg | 40:80 |
| CD19 | >80 wk | >80 | 40:80 | >80 | >80 | 40:80 |
| CD20 | >80 wk | >80 | >80 | >80 | >80 stg | >80 |
| CD23 | >80 longer | 5-20 | 40:80 | 5-20 | <5% | 20:40 |
| CD25 | 20:40 wk | 20:40 wk | 5-20 wk | 20:40 | >80 | 5-20 |
| CD38 | 20:40 | >80 | >80 | >80 | 20:40 | >80 |
| CD43 | >80 | 40:80 | <5% | 20:40 | 40:80 var | 20:40 |
| CD79b | >80 wk | >80 | >80 | >80 | <5% | 40:80 |
| CD103 | <5% | <5% | <5% | <5% | >80 | |
| CD138 | <5% | <5% | <5% | 5-20 | <5% | |
| CD200 | >80 | <5% | <5% | 5-20 | >80 | |
Key to table:
Key to colour code Click for link
Key to expression code Click for link